Controls nausea and vomiting associated with certain types of anesthesia and surgery. ANDA 40596, held by Zydus Pharms USA. Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 40596 (Promethazine Hydrochloride), held by Zydus Pharms USA, was first approved by FDA on Nov 18, 2005, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2005 | Original application | Approved | None posted |
| Promethazine Hydrochloride12.5MG · tablet;oral | Promethazine Hydrochloride | Rx |
| Promethazine Hydrochloride25MG · tablet;oral | Promethazine Hydrochloride | Rx |
| Promethazine Hydrochloride50MG · tablet;oral | Promethazine Hydrochloride | Rx |
| Apr 17, 2007 | Supplement 4Labeling | Approved | None posted |
| Nov 18, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters